Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: Frequency and ultrasound findings

Journal of Endocrinological Investigation

Volumn 38, Issue 8, 2015, Pages 849-857

  Jeong, S H ^a   Hong, H S ^a   Kwak, J J ^a   Lee, E H ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Follicular; Human genes; PAX8 PPAR fusion protein; RAS mutations; Thyroid cancer

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAS PROTEIN; TRANSCRIPTION FACTOR PAX8; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCIFICATION; CODON; ECHOGRAPHY; FEMALE; FOLLICULAR THYROID ADENOMA; FOLLICULAR THYROID CARCINOMA; FUSION GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; POINT MUTATION; THYROID TUMOR; VERY ELDERLY; ADENOCARCINOMA, FOLLICULAR; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; GENETICS; HEALTH SURVEY; MIDDLE AGED; MUTATION; ONCOGENE RAS; THYROID NEOPLASMS; YOUNG ADULT;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PAIRED BOX TRANSCRIPTION FACTORS; POPULATION SURVEILLANCE; PPAR GAMMA; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84937434539     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-015-0311-x     Document Type: Article

References (24)

1. Grebe SK, Hay ID (1995) Follicular thyroid cancer. Endocrinol Metab Clin North Am 24(4):761-801
2. DeLellis RA (2006) Pathology and genetics of thyroid carcinoma. J Surg Oncol 94(8):662-669
3. D'Avanzo A, Treseler P, Ituarte PH et al (2004) Follicular thyroid carcinoma: histology and prognosis. Cancer 100(6):1123-1129
4. Nikiforova MN, Lynch RA, Biddinger PW et al (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88(5):2318-2326
5. Lin JD, Chao TC (2006) Follicular thyroid carcinoma: from diagnosis to treatment. Endocr J 53(4):441-448
6. Nikiforov YE (2008) Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(2):S37-S43
7. Banito A, Pinto AE, Espadinha C, Marques AR, Leite V (2007) Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf) 67(5):706-711
8. Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4(10):1474-1479
9. Suarez HG, du Villard JA, Severino M et al (1990) Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5(4):565-570
10. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE (1999) Prevalence of ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50(4):529-535
11. Marques AR, Espadinha C, Catarino AL et al (2002) Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87(8):3947-3952
12. Marques AR, Espadinha C, Frias MJ et al (2004) Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer 91(4):732-738
13. Mazzaferri EL (1993) Management of a solitary thyroid nodule. N Engl J Med 328(8):553-559
14. Fernández-Medarde A, Santos E (2011) Ras in cancer and developmental diseases. Genes Cancer 2(3):344-358
15. Forbes SA, Bindal N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945-D950
16. Park KY, Koh JM, Kim YI et al (1998) Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf) 49(3):317-323
17. Kim HJ, Jang HW, Sohn SY et al (2012) Frequency of RAS mutations and PAX8/PPARgamma rearrangement in follicular thyroid tumors in Korea. Endocrinol Metab 27(1):45-53
18. Garcia-Rostan G, Zhao H, Camp RL et al (2003) Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21(17):3226-3235
19. Fukahori M, Yoshida A, Hayashi H et al (2012) The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 22(7):683-689
20. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C (2003) Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88(6):2745-2752
21. Yoshimoto K, Iwahana H, Fukuda A et al (1992) Ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 83(10):1057-1062
22. Liu RT, Hou CY, You HL et al (2004) Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid 14(8):616-621
23. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA (1994) Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30A(7):987-993
24. McIver B, Grebe SK, Eberhardt NL (2004) The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 4(3):221-234